Abstract: Statins used in the treatment of dyslipidemias are top-selling drugs in the world. Economical production of statins in industrial scale is challenging, because the side chain of statins is a 3,5-dihydroxyacid derivative consisting of two asymmetric centers. The most prominent methods for the preparation of the side chain are based on biocatalysis and surveyed in this review.
Two short surveys have been written on the subject thus far [13, 14] . In addition, a thorough review about 1,3-diols was recently published [15] . The present review covers the main biocatalytic methods used: carbonyl reductions (I), dehalogenase-catalysed processes (II), usage of nitrilases or nitrile hydratases/amidases (III), lipase-, esterase or protease-catalysed reactions (IV) and processes based on aldolases (V), Fig. (3) . Hydrolytic enzymes can also be used for the kinetic resolution of various intermediates. Trend is, however, clearly in the use of the so-called "meso-trick" or in other desymmetrisations of prochiral compounds which enable the transformation of a prochiral subtrate into one enantiomer as comes out in this review. C 3 -synthons like epichlorohydrin 11, a wide area of its own, has already been well reviewed and, as a consequence, excluded from this review [16, 17] . and they may have an inhibitory effect on the biocatalyst. Bioreductions using either whole cells or purified dehydrogenases have been profoundly studied in over 100 reports published by 2009. This stems from the fact that both enantiomers of 4-chloro-3-hydroxybutanoate are valuable synthons. Besides using the S-enantiomer as a building block for the statin side chain, the R-enantiomer serves as a starting material e.g. for L-carnitine [18] . Dehydrogenases catalysing the reduction of prochiral 4-chloroacetoacetate 12 into (S)-13 have been found in dozens of microorganisms. Therefore, only bioreductions encompassing emphasis on a further scale-up are next discussed. Baker's yeast (S. cerevisiae) as a commonly used inexpensive, readily available and handled whole cell biocatalyst has been included as well [19] . Whole Cell Systems -S. cerevisiae produces several reductases that differ in stereoselectivity [20] [21] [22] [23] . This is why the enantiomeric excess of the product is often low, and opposite enantiomers can be obtained by varying the reaction conditions. Although optimisation of the reaction conditions can be laborious, the outcome is often from good to excellent [24] [25] [26] [27] [28] [29] [30] [31] [32] . Thus, over 90% yields and ee p typically 90-95% have been reported for (S)-13a and (S)-13b. Low substrate concentrations often favour bioreduction by baker's yeast. To overcome the need to use low substrate concentrations in scaleups, 12b has been embedded in adsorbing resins [33, 34] . In these approaches, it was possible to increase the initial substrate concentration from 0.070 M to 0.150 M by releasing the substrate slowly into the reaction solution, leading to the corresponding enhancements on optical purity of (S)-13b from 78% to 95% [34] . Both substrate inhibition and the spontaneous chemical hydrolysis of 12b were decreased as well. As another whole cell-system, fungus Aureobasidium pullulans CGMCC 1244 in phosphate buffer (0.1 M, pH 7.5) and dibutylphthalate gave 56 g/dm 3 (0.34 M) of (S)-13b at 97% ee and 94% molar conversion [35] .
Pharmaceutical industry today is pursuing short R&D timelines for product launching to gain enough revenues to balance the high cost of drug development during the short life time of patents. Accordingly, many pharmaceutical manufacturers rely on high throughput screening (HTPS) methods in the biocatalytic process development. In Kaneka, 400 different yeast strains were screened for an efficient enantioselective biocatalyst to be used in the reduction of 4-chloroacetoacetate 12b [36] . Using the cells of Candida magnoliae, 12b was reduced into (S)-13b with high enantioselectivity (ee 96.6%; 90 g/dm 3 (0.54 M) after 60 h).
Use of Overexpressed Enzymes -An improved method for the enantioselective bioreduction of 4-chloroacetoacetate 12b has been built on the above HTPS-study, Fig. (4) , Table 1 (entry 1) [37, 38] . The method is based on the Escherichia coli strain HB101 which I.
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CO 2 R OR' O X expresses NADPH-dependent carbonyl reductase S1 from C. magnoliae and for the coenzyme recycling glucose dehydrogenase (GDH) from Bacillus megaterium. GDH catalyses the oxidation of inexpensive D-glucose into gluconolactone which then decomposes spontaneously into gluconic acid. 12b is susceptible to chemical background hydrolysis, and therefore it was fed continuously into the culture broth, keeping its concentration below 0.06 M. When nbutyl acetate-water was used as a solvent, the concentration of the (S)-13b (ee 100%) in the organic phase amounted to 430 g/dm 3 (2.58 M; yield 85%) in 34 h. This is among the highest product concentrations of (S)-13 reported in the literature. In addition to recombinant E. coli, recombinant Pichia pastoris was successfully used for the production of (S)-13b (0.32 M at the end; ee 95%, yield 91%) in an otherwise similar system [39] . A similar n-butyl acetate/water biphasic system also yielded methyl (S)-4-bromo-3-hydroxybutanoate (0.28 M, 54 mg/mL), except that recombinant E. coli cells served as a catalyst expressing a -keto ester reductase gene from Penicillium citrinum and glucose dehydrogenase [40] .
Scientists at Daicel have taken advantage of the recombinant-DNA technology in designing a biocatalytic method for the preparation of (S)-13b, Fig. (4) , Table 1 (entry 2), [41] . The method is based on E. coli strain that expresses a carbonyl reductase (KaCR1) isolated from Kluveromyces aestuarii. For the coenzyme recycling, the bacterium also expresses formate dehydrogenase (FDH) from Mycobacterium vaccae. FDH uses NAD + as a coenzyme in the reaction of formic acid into carbon dioxide. FDH can be seen as an excellent choice for the coenzyme recycling as compared to GDH. FDH uses inexpensive formic acid as a substrate, and the reaction is irreversible. Further, the reaction product, carbon dioxide, does not inhibit the carbonyl reductase, and removal of the carbon dioxide from the reaction is easy. FDHs, on the other hand, have relatively low activity, and they are labile to -haloketones. This is why the structure of the FDH has been improved by mutagenesis techniques. The mutations have been targeted to structurally nonconservative cysteine residues in the FDH structure. By using the bioreduction developed by Daicel, (S)-13b can be produced in 49.9 g/dm 3 (0.30 M) with very high enantioselectivity (ee > 99%).
Regeneration of NAD(P) + can be achieved also by using a second substrate. For this purpose, 2-propanol is commonly used due to its chemical properties and low cost. This type of system has been used with recombinant E. coli cells where the gene encoding Leifsonia alcohol dehydrogenase has been cloned and expressed, Fig. (4) , Table 1 (entry 3) , [42] . Many ketones have been reduced with over 99% ees on 100 mg/mL scale. The production of (S)-13b reaches a level of over 350 g/dm 3 (2.13 M) in the reaction mixture.
Preparation of (3R,5S)-Dihydroxyhexanoates
(S)-5-Hydroxy-3-Oxohexanoate as a Substrate
Compared to (S)-4-chloro-3-hydroxybutanoate (S)-13, (3R,5S/R)-dihydroxyhexanoates (3R,5S/R)-15a-c are more advanced building blocks for the statin side chain, because their structure includes both required asymmetric centers with hydroxyl groups, Figs. (5) and (6) . (3R,5S/R)-dihydroxyhexanoates can be prepared, for instance, by reducing diastereoselectively the keto-group of the corresponding enantiopure -hydroxyketone (S/R)-14a-c. As a drawback, the chemical reduction often requires low temperature (-80 ºC) [43] .
A chemo-enzymatic method for the diastereoselective reduction of tert-butyl (S)-5,6-dihydroxy-3-oxohexanoate (S)-14a has been developed at Avecia Pharmaceuticals. The process is based on catalysis by a carbonyl reductase from Pichia angusta using 25 g/dm 3 (0.11 M) of (S)-14a, Fig. (5) [44] . The product (3R,5S)-15a was isolated with 80% yield and over 99% diastereomeric excess. In this bioreduction whole microbe cells can be used, in which case the coenzyme is regenerated by the normal metabolism of the microbe cells. The method also utilised lipase-catalysed regioselective acetylation by immobilised Candida antarctica lipase B. This regioselective acetylation at the position 5 of (3R,5S)-15a allowed direct protection of the hydroxyl groups of (3R,5S)-16 with 2,2-dimethoxypropane and the removal of the acetyl group in the next steps. The precursor (3R,5S)-17 for the statin side chain was thus obtained.
The same microbe has also been patented for the preparation of tert-butyl (3R,5R)-3,5-dihydroxy-6-cyanohexanoate (3R,5R)-15b 3 (0.074 M) of the product (3R,5R)-15b (de>99%) was formed at the end (t=48 h, c=79 %). Kaneka has also patented a similar type of bioreduction method where several strains were screened for the preparation of chlorohexanoate (3R,5S)-15c [46] . The optimised method uses carbonyl reductase from Candida magnoliae IFO0705. By using 10 g/dm 3 (0.042 M) of the substrate, the product (3R,5S)-15c was formed with 79% isolated yield and 100% diastereomeric excess (t=18 h).
3,5-Dioxohexanoate as a Substrate
When 3,5-dioxohexanoates are used as substrates, the bioreduction may yield monoalcohols or proceed into the diol, thus leading to the formation of both asymmetric centers in one pot, Fig. (7) . Ethyl and tert-butyl esters of 6-benzyloxy-3,5-dioxohexanoic acid (18a and 18b, respectively) can be reduced selectively into the corresponding (3R,5S)-dihydroxyesters (3R,5S)-21 with the cell extract of Acinetobacter sp. SC13874 [47] . Reduction of the ethyl ester 18a produced (3R,5S)-21a with enantiomeric excess of 99% and diastereomeric excess of 63%. Reduction of the tert-butyl ester 18b produced, on the other hand, a mixture of mono-and dihydroxyesters (62% and 35%, respectively). Ee of the desired syn-diol (3R,5S)-21b produced from tert-butyl ester was 87% and de 51%. Three different carbonyl reductases have been isolated from A. calcoaceticus. Carbonyl reductase III is the enzyme responsible for the double reduction of ethyl 6-benzyloxy-3,5-dioxohexanoate 18a into syn-(3R,5S)-dihydroxyhexanoate 21a. The other reductases catalyse the formation of monoalcohols (carbonyl reductase I) and the formation of dialcohols from monoalcohols (carbonyl reductase II).
Alcohol dehydrogenase from Lactobacillus brevis was observed to catalyse the regio-and enantioselective reduction of tert-butyl 6-chloro-3,5-dioxohexanoate (22; 0.020 M) into (S)-6-chloro-5-hydroxy-3-oxohexanoate (S)-14c with 72% isolated yield and very high enantioselectivity (ee > 99%), Fig. (8) [48] . The double reduction of 22 is possible with the resting cells of Lactobacillus kefir [49] . There are two alcohol dehydrogenases (ADH) in the microbe L. kefir: ADH1 reduces the carbonyl group at the position 5 (ee[(S)- [45, 46] . Fig. (7) . The preparation of (3R,5S)-21 with sequential asymmetric reduction steps [47] . 14c] > 99.5%) and ADH2 the carbonyl group at the position 3. Both enzymes use NADPH as a cofactor, and the recycling can be done with glucose as a cosubstrate. The diastereomeric excess of the product (3R,5S)-15c prepared by this double bioreduction was 99%. The substrate 22 is, however, unstable in aqueous media, and therefore the shift from the batch-fermentation process to the fedbatch process resulted in improvements of 153% in final product concentration and 79% in the yield. The product (3R,5S)-15c has been produced 1 g/dm 3 per hour resulting in 0.12 M final product concentration and 85% yield in the fed-batch fermentation process.
Another way to overcome the problem related to the instability of 22 in aqueous media is to use water-immiscible ionic liquids as co-solvents in the bioreduction. Ionic liquids can store up the waterlabile substrate and thus reduce its decomposition. When 20% (v/v) of BMIM[Tf 2 N] was added in aqueous media, the yield of (3R,5S)-15c for the bioreduction by L. kefir microbe increased from 47% to 81% when 0.4 M substrate was used. However, the distribution of the product between the two different phases makes the extraction difficult, thus the yield was reduced to 65% in practice [50] .
METHODS BASED ON LIPASES, ESTERASES AND PROTEASES
Background
In nature, lipases (EC 3.1.1.3) catalyse the hydrolysis of fatty acid esters, whereas esterases (EC 3.1.1.1) catalyse the hydrolysis of small volatile esters. Proteases (EC 3.4.) are responsible for the hydrolysis of peptide bonds of peptides and proteins. Lipases are the most widely used enzymes in organic synthesis due to their stability, wide substrate tolerance and commercial availability [51] . With lipases, esterases and serine proteases the reactions take place with so-called serine hydrolase mechanism [52] . The reaction goes through two consecutive addition/elimination reactions where the first step results in the formation of the ester intermediate, the socalled acyl-enzyme intermediate, Fig. (9) . The anionic tetrahedral transition states to and forward from this intermediate are stabilised by the oxyanion hole at the active site. Especially lipases and serine proteases are widely used in non-aqueous environment where the added nucleophile Nu 2 H, at least in theory, can be any nucleophile capable of binding to the active site correctly for the reaction. Thus, alcoholysis, aminolysis, thiolysis etc. are catalysed in addition to ester hydrolysis. Hydrolytic enzymes typically catalyse kinetic resolution of racemates with theoretical 50% yield. The trend is toward increasing productivity through the transformation of kinetic into dynamic kinetic resolution and to usage of desymmetrisation of prochiral compounds. Fig. ( 3) describes some possible paths (IV) where lipases, esterases or proteases can be used in the synthesis of building blocks for the statin side chain.
Lipase-Catalysed Kinetic Resolution: -Lactonisation
The -pentanolactone structure can be found, for instance, in the structures of lova-and simvastatins, Fig. (1) . Bonini and his group have developed a lipase-catalysed kinetic resolution method for the preparation of (3R,5R)-pentanolactone side chain analogs of statins [53, 54] . The method is based on porcine pancreatic lipase (PPL) which catalyses the enantioselective lactonisation of the open chain diol 23 into 24, Fig. (10) . In this reaction, the hydroxyl group at the position 5 acts as an intramolecular nucleophile which attacks the carbonyl carbon of the ester group. Intramolecular lactonisation was not detected in control reactions where no enzyme was added. The reaction was optimised with respect to temperature, solvent and its water content. The reaction was fastest in toluene, although most enantioselective in diethyl ether. The best result, the 50% conversion and ee p over 98%, was achieved either using diethyl ether as a solvent at 40 °C or using diethyl ether and molecular sieves at 23 °C. The reaction suffers from long reaction times (168 h).
Lipase-Catalysed Desymmetrisation of a Meso-Syn-Diol
Bonini et al. describe a lipase-catalysed desymmetrisation of 1,7-di-O-acetate of meso-1,3,5,7-heptanetetrol 25 which is protected as an acetonide, Fig. (11) [55] . The method utilises Pseudomonas fluorescens lipase which recognises the enantiotopic acetyl groups of a prochiral starting material and thus selectively catalyses the hydrolysis of one of the two ester groups. Using this method, the compound (3S,5R)-26 (0.58 M) was produced with over 98% 
Desymmetrisation of 3-Hydroxyglutaric Acid Derivatives
Desymmetrisation of prochiral 3-hydroxyglutaric acid derivatives is an attractive choice for obtaining the required enantiomer for the statin side chain. Lipase-, esterase-or protease-catalysed hydrolysis or ammonolysis of 3-hydroxyglutaric acid esters like 27 is the most widely studied reaction. Ring-opening of 3-O-protected hydroxyglutaric anhydride has also been studied, even though rather seldom used in practice [56] . It was early noticed that pig liver esterase (PLE) and -chymotrypsin are among the enzymes displaying highest enantioselectivity [57] [58] [59] [60] [61] [62] . Due to the animal origin, PLE has not found a wide large-scale use, whereaschymotrypsin-catalysed reaction has been scaled up [63, 64] . In 2003, Öhrlein and Baisch at Ciba Speciality Chemicals published an optimised method for the preparation of the statin side chain using diethyl 3-hydroxyglutarate 27 as the starting material in a chemo-enzymatic process, Fig. (12) . In the first step of the synthesis, the hydroxyl group was acylated into the methoxyacetate 28. Next, one of the asymmetric centers of the statin side chain was prepared with the -chymotrypsin-catalysed hydrolysis of 28 (400.5 g; 1.0 M) in phosphate buffer (pH 7.8), producing (R)-29 with high enantioselectivity (ee 98%) and yield (94 %). Only one of the ester groups was hydrolysed, evidently due to the charged carboxylate group of the product. In the third step, the transformation of the free acid group of (R)-29 into the acid chloride with oxalyl chloride followed by the Friedel-Crafts type reaction with aluminium trichloride and ethene furnished the chain elongation. The PLEcatalysed hydrolysis of the methoxy acetal group of (R)-30 was selective leaving the ethyl ester group unreacted. Finally, the other asymmetric center was created in (R)-31 in the presence of borane as a catalyst. Protection of (3R,5S)-32 with 2,2-dimethoxypropane, and substitution of the chlorine with the azide group gave (3R,5R)-33 with enantiomeric and diastereomeric excesses of 98% and 97%, respectively, to be inserted as the side chain of atorvastatin.
Lipase-and esterase-catalysed hydrolysis and amino/ammonolysis of diethyl 3-hydroxyglutarate has also been used for obtaining the building block for the statin side chain, Fig. (13) . From lipases, Candida antarctica lipase B (CAL-B) has been among the most potential alternatives [65] [66] [67] [68] . CAL-B-catalysed hydrolysis of 27 Fig. (11) . The chemoenzymatic synthesis of (3R,5R)-3-hydroxy-5-(2-phenylethyl)-pentanolactone (3R,5R)-24 which utilises enantioselective hydrolysis catalysed by Pseudomonas fluorescens lipase [55] . Fig. (12) . The synthesis of the atorvastatin side chain (3R,5R)-33 based on -chymotrypsin-catalysed enantioselective hydrolysis [63] . 
METHODS BASED ON ENZYMATIC NITRILE HYDRO-LYSIS 4.1. The Hydrolysis of Nitriles in Nature
There are two different enzymatic routes of nitrile hydrolysis in nature [70] . Firstly, a nitrile can be hydrolysed directly into a carboxylic acid by nitrilases (EC 3.5.5.1), Fig. (14, a) . Secondly, a nitrile can be hydrolysed into a carboxylic acid via an amide intermediate by nitrile hydratase (EC 4.2.1.84) followed by amidase, proposing that these two enzymes exist in a same organism, Fig.  (14, b) . There is a catalytic triad composed of glutamate, lysine and cysteine in the active site of nitrilases [71] . Nitrile hydratases, on the other hand, are metalloenzymes that have iron (III)-or cobalt (II)-ions acting as Lewis acids in the active site. Thiolate groups in the active sites of both enzymes also contribute to catalysis. The microbes expressing nitrilase or nitrile hydratase and amidase enzymes have been used in the desymmetrisations of 3-substituted glutaronitriles in the synthesis of the statin side chain [III, Fig. (3) ].
Brevibacterium and Rhodococcus Strains: Nitrile Hydratase and Amidase
Rhodococcus butanica ATCC 21197 was reported in early 1990s to hydrolyse 3-benzyloxyglutaronitrile 37a to give the product (S)-38a with 68% yield and 88% ee, Fig. (15) [72] . Enantioselectivity was enhanced (ee 99%, yield 71%) when the O-protective group was changed to benzoyl. Later in 1996 scientists at Zeneca and University of Exeter described a method in which 3-benzyloxyglutaronitrile 37a was selectively hydrolysed into the (S)-4-cyanoacid (S)-38a by Brevibacterium R312 strain [73] . The microbe expresses nitrile hydratase and amidase which catalyse the formation of the acid (S)-38a through an amide intermediate. Using this method, (S)-38a was produced with moderate enantioselectivity (ee 88%) and 65% yield. Next, a silyl ether protected intermediate (R)-39 was produced from (S)-38a in six chemical steps. After removal of the TBS-protection, the nitrile group was hydrolysed into (R)-40 with Rhodococcus SP361-microbe. Although the microbial step is not stereoselective, it is advantageous because of mild hydrolysis conditions compared to those in chemical hydrolysis. Finally, the hydroxyl group of (R)-40 was protected again, yielding the statin side chain as -lactone (3R,5S)-41 with enantiomeric excess of 88% and diastereomeric excess of 50%.
The Chase for Efficient Nitrilases
The scientists at Diversa have searched for new efficient nitrilases for the desymmetrisation of 3-hydroxyglutaronitrile 42, Fig.  (16) . The nitrilases have been searched with two systems that are complementary to each other. Robertson and his group sequenced DNA samples isolated from over 600 different environments and compared the sequences of the enzymes to the substrate selectivity. A group of (R)-selective nitrilases was found, although only two of the nitrilases catalysed the production of the important precursor (R)-4-cyano-3-hydroxybutanoic acid with enantiomeric excess of over 95% [74] .
In another system, DeSantis et al. at Diversa used directed protein evolution for finding efficient nitrilases [75] . Laboratory-based directed protein evolution is used for increasing the mutagenetic phenomena belonging to normal evolution [76] . In this way, for instance, the mutations that improve the catalytic properties of enzymes can be found and the enzyme structure rationally modified by combining beneficial mutations. DeSantis et al. used a patented Gene Site Saturation Mutagenesis TM technology for the creation of Fig. (13) . The preparation of ethyl (R)-4-cyano-3-hydroxybutanoate (R)-36 from diethyl 3-hydroxyglutarate using CAL-B or esterase (CLS-BC-14011) [65] [66] [67] [68] [69] . Fig. (14) . The enzymatic hydrolysis of nitriles with a) nitrilase b) nitrile hydratase and amidase [70] . Scientists at Dowpharma have developed a three-step synthesis of ethyl (R)-4-cyano-3-hydroxybutanoate (R)-36b which is based on an enantioselective hydrolysis catalysed by nitrilase BD9570, Fig. (16) [78] . Nitrilase BD9570 comes from Diversa. It is expressed in Pseudomonas fluorescens microbes with Pfenex-technology. P. fluorescens grows to very high cell densities, and the target protein can be produced in soluble, active form. The quantity of the protein produced is also very high, over 50% of the total cell protein. The starting material for the synthesis of (R)-36b was inexpensive epichlorohydrin 11 from which 3-hydroxyglutaronitrile 42 was produced in two steps. Next, asymmetry was created by hydrolysing 3-hydroxyglutaronitrile (3 M; 330 g/dm 3 ) into (R)-4-cyano-3-hydroxybutanoic acid (R)-43 in 16 h with 100% conversion and 99% ee. Finally, (R)-43 was transformed into the ethyl ester (R)-36b. The challenges of the method are, however, the difficult industrial synthesis of 3-hydroxyglutaronitrile, and the problematic isolation of (R)-43 from the cell debris and salts. These complications were reported to affect the total yield of the process, decreasing it to 23%.
METHODS BASED ON HALOALCOHOL DEHALO-GENASES 5.1. Background
Haloalcohol dehalogenases (HHDH; EC 4.5.) have an important role in bacterial detoxification of halogenated xenobiotics. Vicinal haloalcohols 44 are transformed into epoxides 45 and vice versa, Fig. (17) [79] . The hydroxyl group of 44 then acts as an intramolecular nucleophile which substitutes the halogen atom X of the substrate. In the reverse reaction the halide anion attacks the epoxide ring which thereby opens up, Fig. (18) . HHDH also accepts other nucleophiles in addition to halides. Good examples are cyanide-, azide-and nitrite ions which make HHDH valuable in the Fig. (15) . The chemo-enzymatic preparation of the statin side chain (3R,5S)-41 from 3-benzyloxyglutaronitrile 37 using Brevibacterium R312 [72, 73] . Fig. (16) . The chemoenzymatic synthesis of ethyl (R)-4-cyano-3-hydroxybutanoate (R)-36b using nitrilase BD9570 [78] . synthesis of enantiopure statin side chains [80] . The specificity of HHDH for certain nucleophiles is probably due to the selective interactions of the nucleophile with the enzyme structure in the halide ion binding site. It is proposed that the halide ion binding site is linear because of the nearly linear molecular geometry of the cyanide-, azide-and nitrite ions [79] . Haloalcohol dehalogenases have been successfully used for the preparation of various C 3 -synthons which can also be employed as building blocks for the statin side chain. The area has already been thoroughly reviewed by Suzuki and Kasai [16, 17] . This review concentrates on more advanced building blocks which can be obtained through paths II of Fig. (3) . Fig. (17) . The dehalogenation of a vicinal halo alcohol 44 into an epoxide 45 catalysed by haloalcohol dehalogenase.
Ethyl (R)-4-Cyano-3-Hydroxybutanoate
Ethyl (R)-4-cyano-3-hydroxybutanoate (R)-36b can be prepared chemically by the reaction between ethyl (S)-4-chloro-3-hydroxybutanoate and sodium cyanamide [81] . The reaction gives, however, numerous by-products which makes the purification of the crude product difficult by fractional distillation under reduced pressure (10 torr).
In 2006, Codexis was awarded the Green Chemistry prize for the manufacturing process of (R)-4-cyano-3-hydroxybutanoate by the U.S. Environmental Protection Agency (EPA) [82, 83] . The process is completely based on enzyme catalysis. The method utilises three enzymes: carbonyl reductase, haloalcohol dehalogenase and glucose dehydrogenase for the recycling of the coenzyme NADPH. The process is advantageous because it can be run under mild, sustainable conditions providing environmental benefits. Moreover, the crude product does not need purification by fractional distillation that is unavoidable in the chemical process. Additionally, the sequential reactions can be performed in one pot. In this method, prochiral ethyl 4-chloroacetoacetate 12b is reduced into ethyl (S)-4-chloro-3-hydroxybutanoate (S)-13b with carbonyl reductase of Candida magnoliae in the presence of glucose dehydrogenase, NADP + and glucose, Fig. (19) . When 100 g of the starting material 12b was used, 87 g of the product (S)-13b was isolated with 86% yield [83] . The reduction by C. magnoliae carbonyl reductase have originally been developed by Kaneka (section 2.2), whereas the kinetic properties of both carbonyl reductase and glucose dehydrogenase have been improved in the method of Codexis [84, 85] . In the next stage, structurally modified haloalcohol dehalogenase of Agrobacterium radiobacter AD1 catalyses dehalogenation into the epoxide (S)-46b followed by the ring opening with the cyanide-ion. Stereochemistry is not changed in these steps, which enables the production of (R)-36b with high enantiomeric purity (ee > 99%). When 45 g of the intermediate (S)-13b was used, the isolated (R)-36b amounted to 28.5 g (66%) [84, 86] . The product (R)-36b manufactured by this optimised method has been used in the synthesis of atorvastatin.
The starting material 12b of the method of Codexis is an efficient inhibitor of HHDH [86] . Because some of it always remains unreacted, the catalytic activity of HHDH can be reduced. Advantageously, both the substrate and also the product inhibition of the HHDH have been overcome by manipulating the enzyme structure. In addition, the activity of the improved HHDH is 10 000 times higher than that of the wild type HHDH. To summarise, the three enzymes have altogether improved the volumetric productivity of the reduction reaction by 100-fold and that of the cyanation reaction by 4000-fold [82].
Other Applications
It has also been shown that haloalcohol dehalogenases purified from Arthrobacter erithii and recombinant E. coli carrying a gene of Corynebacterium sp. N-1074 catalyse the formation of epichlorohydrin (R)-11 from prochiral 47 and further the ring-opening of the epoxide-ring to form (R)-48 with 95% ee, Fig. (20) [87, 88] . Even though (R)-48 has a seemingly wrong configuration for the statin side chain, it can be further used as a building block, e.g. as described in chapter 3.3 where racemic epichlorohydrin is used for the synthesis of prochiral 3-hydroxyglutaronitrile. Thus, prochiral 1,3-dichloro-2-propanol 47, 3-hydroxyglutaronitrile 42 and racemic or enantiopure epichlorohydrin 11 can all be used as starting materials for the statin side chain.
The laboratory of biochemistry in the University of Groningen and the German chemical manufacturer BASF AG have collaborated in developing a sequential, haloalcohol dehalogenase-based kinetic resolution of methyl 4-chloro-3-hydroxybutanoate 13a, Fig.  (21) [89] . The reaction produces (R)-46a rather than the opposite Fig. (18) . Epoxide ring opening catalysed by haloalcohol dehalogenase [79] . Halide binding site Halide binding site (S)-enantiomer which is the one needed for the synthesis of the statin side chain. The formation of the epoxide (stage 1) is, however, reversible, and thus results in an equilibrium which finally leads to the racemisation of both the (R)-46a and (S)-13a. This problem has been solved by adding cyanide into the system to react with the epoxide into the stable (S)-36a. An additional advantage of this sequential kinetic resolution is that the removal of (S)-46a by the HHDH catalysis enhances the reactivity in the first step. Finally, methyl (S)-4-chloro-3-hydroxybutanoate (S)-13a can be isolated with 95% enantiomeric excess and 41% yield. The kinetic resolution uses haloalcohol dehalogenase from A. radiobacter AD1 which has been modified by changing the tryptophan 249 to phenylalanine. The tryptophan residue 249 is in the loop that forms the halide ion binding site in the structure of the enzyme. The replacement results in the faster release of the halide ion from the binding site, which consequently speeds up the dehalogenation reaction [90] .
ALDOLASE-CATALYSED METHODS
Background
Aldol reactions are among the most important organic reactions for creating new carbon-carbon bonds [91] . In a so-called crossaldol reaction, an enolate anion 50 formed from a carbonyl com- Fig. (19) . The enzymatic synthesis of ethyl (R)-4-cyano-3-hydroxybutanoate (R)-36b from ethyl 4-chloroacetoacetate 12b utilising carbonyl reductase, haloalcohol dehalogenase and glucose dehydrogenase [83] [84] [85] [86] . Fig. (20) . Preparation of (R)-48 from prochiral 47 [87, 88] . Fig. (21) . The enzymatic kinetic resolution of methyl 4-chloro-3-hydroxybutanoate 13a with haloalcohol dehalogenase [89] . HHDH from Agrobacterium radiobacter AD1, NaCN pound 49 attacks the carbonyl group of the other carbonyl compound 52, Fig. (22) . The reaction easily turns complicated and leads to a number of by-products. Provided that both carbonyl compounds, like 49 and 52, have acidic -hydrogens, both of them can likewise form an enolate ion. If unsymmetrical ketones are used as starting materials, the number of enolate ions formed is even higher. The by-product 54 is formed when water is eliminated from the aldol adduct 53. Bearing in mind these drawbacks, the use of an aldolase enzyme (EC 4.1) to catalyse an aldol reaction has many benefits over chemical aldol reactions. Firstly, an enzymatic reaction is specific under mild conditions. Secondly, when a racemic aldehyde is used as a starting material, usually only one of the two enantiomers reacts, because the nucleophile attacks only one of the diastereotopic faces of the carbonyl group [92] .
2-Deoxy-D-ribose-5-phosphate aldolase (DERA, E.C. 4.1.2.4.) catalyses in vivo the reaction of D-glyceraldehyde-3-phosphate and acetaldehyde into 2-deoxy-D-ribose phosphate found in DNA, Fig.  (23) [93] . DERA belongs to class I aldolases, the catalytic mechanism of which is based on the presence of the lysine residue in the active site of the enzyme [94, 95] . The free amino group at the ly- Fig. (22) . The mechanism of an aldol reaction and the subsequent elimination reaction in basic conditions. 
(R)-56 57
-H 2 O sine structure forms a Schiff's base with the carbonyl compound. Enamine formed from the Schiff's base then attacks the carbonyl group of an accepting carbonyl compound. DERA is evidently the only known aldolase that catalyses a cross-aldol reaction of aldehydes in nature [91] .
DERA in the Statin Side Chain Synthesis
Wong with his coworkers at Scripps Research Institute in USA has published the first study in which DERA was used for catalysing an aldol reaction [96] . It was noticed that DERA accepts a wide range of non-natural substrates. Acetone, fluoroacetone and propanal are examples of compounds that can substitute acetaldehyde as a nucleophile in the aldol reaction, Fig. (24) [92, 96] . Several different electrophiles can also be used in the aldol reaction catalysed by DERA. Reactivity somewhat depends on the structure of an electrophile. When 2-hydroxyaldehydes (R)-56 or 58a-g were used reactivity was relatively good when compared to the electrophiles 59-62 without a hydroxyl group at the position 2. (R)-Enantiomers of 56 and 58 were better substrates than the (S)-enantiomers. The nature of the substituent at the position 2 of the electrophile is also known to affect the stereochemistry of the product in such a way that hydrophilic substituents mainly result in the formation of (S)-isomers [97] . Substantially lower reactivities were observed when substrates other than D-glyceraldehyde-3-phosphate (R)-56 were used. Otherwise the substituent at the position 3 had little effect on reactivity. This is at least partly due to the lacking phosphate group in the structures of other non-natural substrates.
In 1994, Wong et al. described a method in which DERA catalysed two sequential aldol reactions [98] . In this tandem aldol reaction acetaldehyde 55 acts as a nucleophile that attacks stereoselectively to the carbonyl group of the other aldehyde 55, 59, 63a or 63b, Fig. (25) . The aldol adduct 64 produced reacts further with another acetaldehyde molecule producing stereoselectively 2,4-dideoxyhexose 65. The linear aldose cyclises spontaneously to the lactol 66 which can be further oxidised into the corresponding lactone 10. The method is a simple way to prepare from inexpensive starting materials the statin side chain resembling HMG-CoA moiety.
Substrates that cannot form a cyclic hemiacetal 67 after the first aldol reaction work best in the reaction, Fig (25) . Thus, the adduct formed in the reaction between hydroxyacetaldehyde and acetaldehyde cyclises into the stable hemiacetal 67 which does not readily attend the next aldol reaction. This, consequently, reduces the yield of the lactol 66. Increase in the enzyme content enhances the product 65 and also the lactol formations. In a reaction between chloroacetaldehyde 59 and acetaldehyde 55 the best yield (70%) of the lactol was achieved when 500 U of DERA per mmol of chloroacetaldehyde were used. When the amount of DERA was only half under the otherwise same conditions, the yield of the lactol decreased to 13%. The lactones 10 obtained by the oxidation of the aldol reaction products 66 can be used as building blocks in the synthesis of the statin side chains.
Although the amount of DERA needed in the reaction has been quite high, the fact that DERA has been readily available has somewhat expedited the method development. The Escherichia coli -bacterium's deoC gene coding for DERA has been cloned and overexpressed in E. coli host cells in Wong's research, and the enzyme has proven to be relatively stable. Thus, 70% of the enzyme activity was still available after ten days in 25 °C at pH 7.5. In the course of the last years, the tandem aldol reaction catalysed by DERA has been markedly improved by manipulating the enzyme structure to make the process suitable for industrial manufacture of the statin side chain.
Industrial Process Development
Expanding the Substrate Specificity
Originally the optimisation of the enzymes was based on rationally designed structure modifications on the basis of the crystal structure. This approach is, however, successful only up to a certain point. In 1990s laboratory-based directed protein evolution gained more ground in the development of biocatalytic methods. The goal is to create a large number of protein variants which are then screened for improved biocatalytic activities. Because the mutant libraries consist of 10 6 -10 8 variants, the need for efficient and specific high throughput screening methods is very high. Nowadays, the methods based on the crystal structure and directed protein evolution are combined in the enzyme optimisation processes.
In 2003 Wong et al. published a study where the activity of DERA towards unphosphorylated substrates was improved by site specific mutagenesis [95] . The mutation spots were designed on the basis of the crystal structure of the enzyme-substrate complex. In the study, variant enzymes were screened in terms of catalytic activity by using the retro-aldol reaction of deoxyribose. The binding pocket for phosphate group consists of nine amino acid residues in the structure of DERA: Gly171, Lys172, Gly204, Gly205, Val206, Arg207, Gly236, Ser238 and Ser239. Of these residues only serine 238 forms a direct hydrogen bond to the negatively charged phos- Fig. (24) . The relative rates of DERA-catalysed aldol reaction with different electrophiles when the nucleophile in the reaction is acetaldehyde. The relative rate of natural substrate, D-glyceraldehyde-3-phosphate, is 100 [92] . Then the methyl ester is transformed into the tert-butyl ester followed by the reduction of the azido group with Ph 3 P, which gives the final product (3R,5R)-73.
Substrate Inhibition and Low Catalytic Activity
The pioneering studies of Wong and his team on the DERAbased biocatalytic synthesis of the statin side chains have gone Fig. (25) . Preparation of the lactone side chain of statins using the reaction catalysed by DERA [98] . Fig. (26) . The chemo-enzymatic synthesis of atorvastatin side chain based on Ser238Asp-DERA-catalysed aldol reaction between 3-azidopropanal 68 and acetaldehyde 55 [99] . through many improvements to be suitable for industrial manufacturers. The highly useful reaction between chloroacetaldehyde and acetaldehyde producing the lactol (3R,5S)-66b, R = Cl, Fig. (25) , has been especially problematic. When the wild type DERA is used, the amount of the enzyme needed is high (20 % w/w). This makes the process expensive as a large scale synthesis. The reaction time is also several days. Another problem is the low concentration of chloroacetaldehyde (100 mM) in the reaction [98, 100] . If the concentration is increased to a level that ensures the efficient production of the lactol, the enzyme is inhibited. These problems have created a need for a new, efficient 2-deoxyribose-5-phophate aldolase which has high activity and which is resistant to chloroacetaldehyde.
DSM has tried to solve the problem by developing variant libraries from the deoC-gene of E. coli K12-strain by error-prone PCR which produces randomised single amino acid mutations to deoC-gene [101, 102] . In the study, variant enzymes were screened for three different features: to decrease inhibition by chloroacetaldehyde, to increase the activity for chloroacetaldehyde and to increase the activity in the aldol reaction of chloroacetaldehyde and acetaldehyde. With HTPS-methods two DERA variants were found to be more active in the presence of chloroacetaldehyde. Additionally, there was found a variant (var 9 ) that produces the lactol (3R,5S)-66b (R = Cl) 14 times more efficiently than the wild type DERA at 0.2 M chloroacetaldehyde concentration. By combining the mutations of var 9 with each of the mutations in the variants resistant to chloroacetaldehyde, two DERA-variants (var 13 and var 14 ) were developed. Variant 14 produced the lactol (3R,5S)-66b (R = Cl) 10 times more efficiently than the wild type enzyme, when the concentration of chloroacetaldehyde was 0.5 M in the reaction, Table 2 .
In the Diversa's study, it was discovered that the inhibition caused by high chloroacetaldehyde concentration can be avoided, when the starting materials are added slowly as a mixture of acetaldehyde and chloroacetaldehyde (2:1) over three hours. In this way the starting materials are consumed as they are added. When the wild-type DERA was used in the aldol reaction, the production of the lactol (3R,5S)-66b (R = Cl) was markedly increased, Table 3 (entries 1 and 2). Under optimised conditions, the wild-type DERA yielded even more lactol than the structurally improved enzyme (var 14 ) developed by DSM (entries 2 and 4). Even greater performance was achieved with improved DERA of Diversa where 93 g/dm 3 (0.558 M) of lactol was produced in 2 h (entry 3). The improved DERA is based on Diversa's search for new DERAs by using genomic libraries that have been constructed from the environmental samples collected from all over the world [100] . Fifteen enzymes have been found to have DERA-activity, and one of them has proved to be highly productive in tandem aldol reaction of chloroacetaldehyde and acetaldehyde. The original organism where this improved DERA has been found is unknown. The sequence of the enzyme found is not similar (< 30%) to the sequence of DERA from E. coli.
The method developed by Diversa has been tested in the production of the lactol (3R,5S)-66b (R = Cl) in 100 g batch process.
The volumetric productivity of the process is nearly 400 times more efficient than in the beginning of the development, having increased from 0.08 g/dm 3 per hour to 30.6 g/dm 3 per hour. Moreover, the amount of the enzyme needed in the process has significantly reduced from 20% (w/w) to 2%, Table 3 . The lactone (3R,5S)-10 (R = Cl) has been obtained by aqueous sodium hypochlorite and acetic acid, and thus the usage of toxic and expensive bromine in the oxidation has been avoided. The enantiomeric and diastereomeric excesses of the lactone produced by this method are over 99.9% and 96.6%, respectively. The diastereomeric excess can be further increased to 99.8% by crystallising the lactone. 
CONCLUSIONS
The methods based on biocatalysis in the preparation of the pharmacophore side chain common to all statin structures have been outlined in this review. The enzymes used are dehydrogenases, haloalcohol dehalogenases, nitrile hydrolysing enzymes, lipases, esterases, -chymotrypsin and DERA. The methods with industrial relevance are collected in Fig. (27) . As shown, the valid enzymatic methods leading to enantio-and diastereopure products can be divided into three main categories, all producing their product with 100% theoretical yields. First, the reduction of keto groups in 12a and 12b, 14a-c (X = HO, CN or Cl) and 22 are all performed using reduction by various microorganisms. The second group is formed by the compounds 25, 27 and 42 where desymmetrisation enables excellent productivities with inexpensive hydrolytic enzymes. The third case, the chemoenzymatic method utilising DERA-catalysed tandem aldol reaction emerges as one of the most efficient ways to prepare the statin side chain (ee > 99.9%, de > 99.6%, 30.6 g/dm 3 per hour). In this method, both asymmetric centers can be prepared enzymatically from inexpensive starting materials 55 and 59 in a single step. In the process developed by Diversa, the reaction conditions have been optimised and the structure of the aldolase used has been modified.
In most of the processes described, the process is sustainable and highly economical, because the desired stereochemistry is introduced to a target molecule under the conditions that are mild and not as complex as in the traditional chemical catalysis due to the need for protecting groups. The requirements for the stereochemical purity (ee > 99.5% and de > 99%) of the statin side chain are met in about half of the methods described here. Facing the truth, the starting point for an efficient enzyme has often been a genomic library or a variant library that has been created in the laboratory by directed evolution processes. The high throughput screening methods in search for the active and chemically stable enzymes and the enzyme structure modification with 3D modeling and gene technol-ogy are the integral parts of biocatalytic method development in modern pharmaceutical research. On the whole, the recent development in the statin side chain synthesis underlines the usefulness of biocatalytic methods which are used alongside with traditional chemical methods, although the chemical part in the process has been left to little attention in the present review. 
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